SELPLG and neoplasm: In this study, we develop a P-selectin glycoprotein ligand-1 (PSGL-1)-decorated liposomes, targeting tumor-associated ECs, loaded with BTZ and BMME-disrupting ROCK inhibitor Y27632 to promote therapeutic efficacy and overcome TME-induced resistance.